Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix and Fluarix Quadrivalent Co-administration Study
NCT01954251Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2013
- Primary completion
- Jun 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of herpes zoster vaccine (recombinant, adjuvanted) in herpes zoster (HZ) (2 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Vaccine Response to Anti-gE Antibodies at Month 3, Vaccine Response for Anti-gE Humoral Immunogenicity at Month 3 and 2 more. Started Oct 2013; status: completed.
02
Drugs
herpes zoster vaccine (recombinant, adjuvanted)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT01954251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01954251.